NCT05638815已完成不适用
An Observational Study to Explore the Role of Alpha-Synuclein-related Biomarkers in the Diagnosis and Disease Evaluation of Parkinson's Disease and Other Synucleinopathies
SciNeuro4 个研究点 分布在 1 个国家目标入组 89 人开始时间: 2021年11月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 89
- 试验地点
- 4
- 主要终点
- To evaluate the difference of α-synuclein-related biomarkers between patients and healthy subjects
研究概览
简要总结
The study is a multi-center, observational study to evaluate the feasibility of α-synuclein-related biomarkers and imaging data in the disease diagnosis and prognosis evaluation in Synucleinopathies and healthy subjects.
详细描述
In the study, a total number of no more than 100 subjects are planned to be enrolled.
Subjects who are eligible for enrollment will be enrolled in the study after signing the informed consent form (ICF) and undergo 3 visits, including the baseline visit (the day of first blood sample collection), visit 1 (day 183 post-enrollment), and visit 2 (day 366 post-enrollment).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •PD subjects must meet the following criteria to be eligible:
- •Age ≥ 40 years old, regardless of gender;
- •Primary PD is diagnosed according to MDS Clinical Diagnostic Criteria for Parkinson's Disease of the International Movement Disorders Association (MDS) in 2015 and the Diagnostic Criteria of Parkinson's Disease in China in 2016;
- •Hohen & Yahr stage 1-3;
- •Receive standard treatment for at least 4 weeks before the screening visit (standard treatment is listed in the Chinese Guidelines for the Treatment of Parkinson's Disease (Fourth Edition));
- •The subject or his/her legal representative is able to understand the content of the informed consent and provide a signed ICF.
- •MSA subjects must meet the following criteria to be eligible:
- •Age ≥ 40 years old, regardless of gender;
- •Patients with probable and possible MSA are diagnosed according to the Second Consensus Statement on the Diagnosis of Multiple System Atrophy and the Chinese Expert Consensus on the Diagnostic Criteria of Multiple System Atrophy in 2018;
- •The subject or his/her legal representative is able to understand the content of the informed consent and provide a signed ICF.
- •Healthy subjects must meet the following criteria to be eligible:
- •Age ≥ 40 years old, regardless of gender;
- •Volunteers who are in good health for their age as determined by clinical examination at the time of screening and who are free from dyskinesia as determined by a complete neurological assessment and from serious systemic disease as determined by a complete history;
- •Be able to understand the content of informed consent and agree to sign ICF.
排除标准
- •Excluded if any of the following criteria is met:
- •Secondary Parkinsonism due to infection, vascular, drugs, poisons, trauma and other causes;
- •Malignant neoplasm (except basal or squamous cell skin cancer) diagnosed within the last 5 years;
- •Those with a known mental illness or substance abuse that will cause them to be unable to cooperate;
- •Patients with severe depression or suicidal behavior (including active attempt, interrupted attempt or attempted attempt) or suicidal thoughts in the past 6 months according to the clinical judgment of the investigator;
- •Pregnant or lactating women;
- •Prior treatment with drugs targeting α-synuclein;
- •Received an investigational drug or device within the previous 4 weeks;
- •The results of laboratory examination and serological virological examination are not suitable for enrollment according to the judgment of the investigator;
- •Other conditions judged by the investigator as not suitable for inclusion.
结局指标
主要结局
To evaluate the difference of α-synuclein-related biomarkers between patients and healthy subjects
时间窗: 12 months
次要结局
- To evaluate the differences of imaging-related indicators in PD, MSA, and their correlation with the disease by brain positron emission tomography (PET)(12 months)
- Attempt to evaluate the correlation between α-synuclein and disease progression by comparing α-synuclein levels at baseline(6 months, and 12 months)
- To evaluate the correlation between α-synuclein levels and imaging data.(12 months)
研究者
研究点 (4)
Loading locations...
相似试验
终止
不适用
A Pilot Biomarker Study Assessing Alpha-synuclein Aggregates Across Biofluid Reservoirs in Patients With SynucleinopathiesNormal Pressure HydrocephalusRapid Eye Movement Sleep Behavior DisorderParkinson DiseaseMultiple System AtrophyNCT04020198Stony Brook University8
已完成
不适用
Systemic Synuclein Sampling Study (S4)Parkinson's DiseaseNCT02572713Michael J. Fox Foundation for Parkinson's Research80
已完成
不适用
Oligomeric Alpha-synuclein in Multiple System AtrophyMultiple System Atrophy (MSA)NCT01485549University Hospital, Bordeaux48
已完成
不适用
Exploring the Relationship Between Alpha-synucleinopathy Related Non-motor Symptom and Post-op. Delirium in Elderly Patients With Spine SurgeryPost-operation DeliriumAlpha-synucleinopathy Related Non-motor SymptomNCT02550626Yonsei University106
招募中
不适用
Research on Novel Biomarkers for Early Diagnosis of Parkinson's Disease:An Observational, Multicenter, Non-Randomized Controlled StudyParkinson's DiseaseNCT06232772Yousheng Xiao600